Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

252
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
252
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

224
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
224
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

203
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
203
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

230
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
230
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

270
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
270
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

380
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
380

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated Mean Corpuscular Hemoglobin Concentration as a Potential Peripheral Biomarker of Parkinson's Disease: A Pilot Case-Control Study in a Mexican Population.

Brain sciences·2025
Same author

Sex-Specific Association Between XPC rs2228001 Polymorphism and Parkinson's Disease Risk in a Mexican Population: A Case-Control Study Exploring Gene-Environment Interactions.

Brain sciences·2025
Same author

Design of a Dual-Drug Delivery System for Local Release of Chlorhexidine and Dexketoprofen.

Polymers·2025
Same author

Synergistic Interaction Between <i>Justicia spicigera</i> Extract and Analgesics on the Formalin Test in Rats.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Antiseptic Surface Based on Antibacterial Polyethylene Composites with Silver Fillers: Stability in Aqueous Solution.

Polymers·2024
Same author

Design of a Whole-Cell Biosensor Based on Bacillus subtilis Spores and the Green Fluorescent Protein To Monitor Arsenic.

Microbiology spectrum·2023

Related Experiment Video

Updated: Aug 10, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.6K

Arsenic: A Perspective on Its Effect on Pioglitazone Bioavailability.

María Cruz Del Rocío Terrones-Gurrola1, Patricia Ponce-Peña2, José Manuel Salas-Pacheco3

  • 1Coordinación Académica Región Altiplano, Universidad Autónoma de San Luis Potosí, Matehuala 78700, Mexico.

International Journal of Environmental Research and Public Health
|February 11, 2023
PubMed
Summary

Arsenic in drinking water reduces cytochrome P450 enzyme function, impacting the metabolism of antidiabetic drugs like pioglitazone in type 2 diabetes patients. This arsenic-induced alteration affects drug bioavailability and therapeutic outcomes.

Keywords:
CYP 450arsenicironmetabolismpioglitazone

More Related Videos

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals
07:39

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

7.4K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Related Experiment Videos

Last Updated: Aug 10, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.6K
A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals
07:39

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

7.4K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Area of Science:

  • Environmental toxicology
  • Pharmacology
  • Biochemistry

Background:

  • Arsenic (As) contamination in drinking water is prevalent in northeastern Mexico.
  • Arsenic exposure reduces cytochrome P450 (CYP 450) enzyme expression.
  • Impaired CYP 450 function affects the metabolism of essential drugs, including oral antidiabetic medications like pioglitazone, crucial for managing type 2 diabetes mellitus (T2DM).

Purpose of the Study:

  • To investigate the impact of arsenic exposure on the metabolism of pioglitazone in patients diagnosed with T2DM.
  • To elucidate the mechanism by which arsenic affects CYP 450 enzyme activity in the context of T2DM.

Main Methods:

  • Collected urine, water, and plasma samples from healthy individuals (n=11) and T2DM patients (n=20).
  • Quantified arsenic levels using fluorescence spectroscopy/hydride generation and pioglitazone concentrations via High-Performance Liquid Chromatography (HPLC).
  • Utilized in silico density functional theory (DFT) to analyze the interaction of arsenic with CYP 3A4 and CYP 2C8 enzymes.

Main Results:

  • T2DM patients exposed to >0.010 ppm arsenic exhibited significantly altered pharmacokinetic parameters (Ka, Cl, ABCt) compared to healthy individuals.
  • In silico analysis revealed that arsenic substitutes iron within the active sites of CYP 3A4 and CYP 2C8 enzymes.
  • These findings indicate a direct molecular interaction between arsenic and key drug-metabolizing enzymes.

Conclusions:

  • Arsenic substitution of iron in CYP 3A4 and CYP 2C8 active sites modifies their enzymatic function.
  • This alteration impacts the metabolic pathways involving CYP 2D6 and CYP 3A4 in T2DM patients.
  • Consequently, arsenic exposure leads to altered pioglitazone bioavailability and reduced therapeutic efficacy in T2DM management.